Berkeley, CA
Kintsugi detects clinical depression and anxiety using machine learning and voice biomarkers. It provides talk therapy software to users in over 250 international cities, and as a result of collecting the worldβs largest longitudinal, annotated voice data for machine learning, it has created the first clinical-grade voice biomarker diagnostic (U.S. Patent-Pending and FDA De Novo pending) to measure the severity of depression and anxiety in real-time.
kintsugihello.comThese are collections Kintsugi is a part of. Click on the collection name to view similar companies.
Corporate Round
$15,000,000
Series A
$20,000,000
Seed
$8,000,000
Grant
$1,000,000
Pre Seed
$150,000
Pre Seed
$1,200,000
Grant
$256,000
Pre Seed
$20,000
Grant
$249,772
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Kintsugi.